Krystal Biotech (NASDAQ:KRYS) Stock Price Expected to Rise, Guggenheim Analyst Says

Krystal Biotech (NASDAQ:KRYS) had its price objective hoisted by stock analysts at Guggenheim from $224.00 to $284.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 2.76% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Zacks Research downgraded shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. The Goldman Sachs Group raised their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 18th. Citigroup increased their price objective on shares of Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $326.25.

Krystal Biotech Price Performance

KRYS opened at $276.36 on Wednesday. The business has a fifty day simple moving average of $268.29 and a 200 day simple moving average of $213.42. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $298.30. The company has a market capitalization of $8.08 billion, a PE ratio of 40.34 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. Equities analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares of the company’s stock, valued at $5,257,200.52. This represents a 39.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dino A. Rossi sold 18,950 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the transaction, the director owned 78,691 shares of the company’s stock, valued at $20,570,614.31. The trade was a 19.41% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 116,611 shares of company stock valued at $30,008,839. Corporate insiders own 13.70% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC grew its stake in Krystal Biotech by 4.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after buying an additional 111,111 shares in the last quarter. State Street Corp grew its position in shares of Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after purchasing an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. raised its stake in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the period. Braidwell LP lifted its holdings in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Krystal Biotech by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock worth $85,174,000 after purchasing an additional 7,194 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.